Lim Guo Hong

Entrepreneur. Volunteer. Technology
Co-Founder, NGH Ventures.
Blogs at

[The Straits Times @straits_times]

China fines https://t.co/WQTqbCgMYU Group $992m over online hotel-booking monopoly https://t.co/U9GcMyjjek

[CNA @ChannelNewsAsia]

Young wushu team shines at 31st SEA Games, ends campaign with 2 gold, 3 silver and a bronze https://t.co/yZIIjXJrSk

[Lim Guo Hong @limguohong]

Rebranding CIO

[Forbes @Forbes]

Our 2022 CIO Next list shows that tech leaders' responsibilities are growing fast—and their job titles are expanding along with them. https://t.co/01Wa3L9dHZ

[Dan Rockwell @Leadershipfreak]

HELP, I’M ALWAYS THINKING ABOUT WORK

I’m asking myself, “Who are you if you aren’t working?”

https://t.co/9K18F0JPlr

#leadership
#LFreakpost

[Lim Guo Hong @limguohong]

"Define the cost of success and be ready to pay it" - #success

[Paul Graham @paulg]

"It is very hard to remember that events now long in the past were once in the future."

— Maitland

[Joseph J Zhao @josephjzhao]

https://t.co/yfYoZ8igbr

[Mohamed E. Salem, MD, FASCO @SalemGIOncDoc]

Very well done Dr. Joseph J. Zhao & colleagues on conducting this study. All of us have been looking for these KM curves. ⁦@JCO_ASCO⁩ #JCO #patients with ⬇️ PD-L1 expression è #Gastric #Esophageal #cancers didn’t benefit from ICIs ⁦@OncoAlert⁩ https://t.co/Em3r8J0M0E

[Joseph J Zhao @josephjzhao]

Congratulations @BenjaminKJTan !!

[Joseph J Zhao @josephjzhao]

Important study - The Tao of bao 👏
Thank you for this work @minhantan
https://t.co/jJylCx7vea

[Joseph J Zhao @josephjzhao]

EBUS-TBNA demonstrates a high yield (∼80.9 to 91.4%) for NGS and the success of EBUS-TBNA sampling for NGS was proportional to the number of passes.
@adrian_kee @yysoon01 @LungCaJournal

https://t.co/QuBGyKR3dQ

[Joseph J Zhao @josephjzhao]

😊🎉 @sundar__raghav @LizzySmyth1 @dominicyap_ @TeoChongBoon @yysoon01 @BenjaminKJTan @Nicholas_Syn @NUSMedicine

[Joseph J Zhao @josephjzhao]

Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma https://t.co/EgLmQE7sRw

[Filippo Pietrantonio @FilippoPietran4]

Thanks to my friend @sundar__raghav for this extremely important work.
For HER2- #gastric #cancer, immunotherapy is not effective, not only in CPS 0 subgroup, but also in CPS 1-4 and 1-9.
For these subgroups, immune-sensitizing strategies are needed!!
https://t.co/EVipZtkAvy

[Lizzy Smyth @LizzySmyth1]

This is innovative and important work in @JCO_ASCO from @sundar__raghav

Computational analysis can accurately derive unpublished subgroup results in clinical trials 🤯🤯 !

This approach has the potential to be a game changer! Well done 👏👏

@OncoAlert
@VJOncology
@myESMO

[Pope Francis – ARCHIVE @Pontifex266Arch]

Today, the Spirit is calling us to heal humanity's wounds with the oil of love. May we, Catholics and Orthodox together, develop forms of cooperation in charity to serve the men and women of our time and to bring them the consolation of the Gospel. #ApostolicJourney

[Kohei shitara @KoheiShitara]

@LizzySmyth1 @OncoAlert @JCO_ASCO @sundar__raghav @VJOncology @myESMO No doubt pts with low CPS has less benefit. Hopefully ongoing studies LEAP-015, Attraction-6, chemo+RegoNivo or other agents (zolbetuximab and bemarituzumab) will improve outcomes of these patients

[Jeroen Dekervel @JDekervel]

This is gold! So useful.

[Joseph J Zhao @josephjzhao]

Drug coated balloons were consistently favoured over percutaneous transluminal angioplasty to prolong target lesion primarypatency and access circuit primary patency. @EJVES_ESVS @toochowwei @fongkhiyung @Nicholas_Syn
https://t.co/SqtJmHYHqQ

[JVIR @JVIRmedia]

Drug-eluting embolic TACE in combination with systemic chemotherapy provided the best oncological outcomes and greatest potential to be converted to resection | Check out the visual abstract below for the recently published paper by Zhao et al. https://t.co/j3YhmXZJG8 #irad